What is the recommended treatment for agrin (AGRN)-related congenital myasthenic syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of AGRN-Related Congenital Myasthenic Syndrome

Ephedrine or its alternatives (pseudoephedrine, salbutamol) are the first-line treatment for AGRN-related congenital myasthenic syndrome, as these patients do not respond to standard anticholinesterase therapy used in other forms of myasthenia.

Primary Treatment Approach

AGRN-related CMS requires a fundamentally different therapeutic strategy than typical myasthenia gravis or other CMS subtypes. Anticholinesterase agents (pyridostigmine) should NOT be used as first-line therapy for AGRN mutations, as they are ineffective in this specific genetic subtype 1.

First-Line Medications

Ephedrine is the established treatment of choice:

  • Both types of AGRN-related CMS respond favorably to ephedrine 1
  • In the French National CMS Network experience, ephedrine was given to 18 patients including 4 with AGRN mutations, with good tolerability and encouraging therapeutic responses even in severely affected patients 1
  • Dosing typically follows standard protocols used for other ephedrine-responsive CMS subtypes

Pseudoephedrine represents an effective alternative:

  • A 2020 case report demonstrated remarkable curative effect with pseudoephedrine in an 8-year-old with AGRN compound heterozygous mutations 2
  • This is the first documented report showing pseudoephedrine effectiveness for AGRN-related CMS 2
  • Consider this option when ephedrine is unavailable or poorly tolerated

Salbutamol (albuterol) serves as another alternative:

  • One patient showed marked response to salbutamol in a 2017 study 3
  • Can be used when patients are allergic to ephedrine, as documented in the French cohort 1
  • However, response may be variable—one patient in the 2020 report showed no improvement with salbutamol 2

Clinical Pitfalls and Monitoring

Common Diagnostic Confusion

AGRN-related CMS patients are frequently misdiagnosed initially:

  • Often suspected of having spinal muscular atrophy (SMA), particularly when mutations affect agrin secretion 4
  • In patients with clinical presentation of SMA but without SMN1 gene mutations, consider AGRN mutations 4
  • May be confused with congenital myopathies due to muscle weakness, atrophy, and scoliosis 1

Key Clinical Features to Recognize

  • Early age of onset (often infancy or birth) 2, 5
  • Muscle weakness predominantly affecting lower limbs initially 2
  • Both distal and proximal muscle involvement 3
  • Fluctuation of symptoms with deterioration in afternoon or hot weather 3
  • Repetitive nerve stimulation shows decremental response (typically 15-17% decrement at 3 Hz) 2, 3

Treatment Monitoring

  • Assess motor function improvement, particularly proximal limb strength
  • Monitor for reduction in fatigability
  • Evaluate bulbar symptoms (dysphagia) if present
  • Track respiratory function in severe cases

Disease Course Considerations

The long-term prognosis varies but AGRN patients generally have less severe disease progression compared to DOK7 mutations 1. Disease patterns can be variable throughout life in individual patients, with potential for:

  • Progressive worsening
  • Periods of exacerbation (pregnancy is a frequent trigger) 1
  • Relative stability with treatment

Why Standard Myasthenia Treatments Fail

The pathophysiology of AGRN-related CMS differs fundamentally from acetylcholine receptor (AChR) deficiency syndromes. AGRN mutations cause:

  • Impaired AChR clustering at the neuromuscular junction 3
  • Protein instability and secretion defects 4
  • Accumulation in endoplasmic reticulum with unfolded protein response 4

Since the problem is not acetylcholine availability or breakdown, cholinesterase inhibitors that increase acetylcholine concentration provide no benefit. Beta-adrenergic agonists (ephedrine, salbutamol) likely work through alternative mechanisms affecting neuromuscular junction function and muscle contractility.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.